Search the Newsreel

Capricor Therapeutics Provides Update on FDA Advisory Committee Meeting for Deramiocel

Capricor Therapeutics announced that the FDA's Cellular, Tissue and Gene Therapies Advisory Committee voted that available evidence did not support the effectiveness of Deramiocel for Duchenne muscular dystrophy cardiomyopathy, with 9 votes against and 3 for. Despite the non-binding negative vote on a narrow …

Capricorn Energy PLC Revenue Breakdown – LSE:CNE

CAPR INVESTOR ALERT: Investigation of Capricor Therapeutics, Inc. Announced by Holzer & Holzer, LLC

ATLANTA, July 30, 2026 (GLOBE NEWSWIRE) -- Holzer & Holzer, LLC is investigating whether Capricor Therapeutics, Inc. (“Capricor” or the “Company”) (NASDAQ: CAPR) complied with federal securities laws. On July 27, 2026, STATNews reported that: “The Food and Drug Administration said Monday that Capricor …

CAPR Alert: Capricor Therapeutics, Inc. (NASDAQ: CAPR) Investors Urged to Contact Hagens Berman; Investigation Opened Following Massive Stock Crash

Hagens Berman has opened an investigation into Capricor Therapeutics (NASDAQ: CAPR) following a significant stock crash after the FDA questioned the company's claims regarding its Duchenne muscular dystrophy drug. The FDA's briefing document revealed discrepancies between Capricor's characterization of its Phase 3 HOPE-3 trial …

Lowey Dannenberg, P.C. is Investigating Capricor Therapeutics, Inc. (NASDAQ: CAPR) for Potential Violations of the Federal Securities Laws

NEW YORK, July 30, 2026 (GLOBE NEWSWIRE) -- Lowey Dannenberg P.C., a preeminent law firm in obtaining redress for consumers and investors, is investigating Capricor Therapeutics, Inc. (NASDAQ: CAPR) (“Capricor” or the “Company”) for potential violations of the federal securities laws. On July 27, …

Capricor stock downgraded at Oppenheimer (CAPR:NASDAQ)

Oppenheimer downgraded Capricor Therapeutics (CAPR) after an FDA advisory committee voted against endorsing its lead drug, Deramiocel. This news caused Capricor's stock to drop over 45%, reaching a new 52-week low.

Capricor Stock Tumbles After FDA Panel Rejects Evidence for Duchenne Cell Therapy

Capricor Therapeutics' stock fell sharply after an FDA advisory panel overwhelmingly rejected the sufficiency of evidence supporting its Duchenne muscular dystrophy cell therapy, Deramiocel. The panel's decision echoed FDA staff concerns regarding post hoc changes to key analyses after the late-stage trial. This rejection …

Duchenne Therapy Has Aug. 22 FDA Action Target After Panel Vote

Capricor Therapeutics announced that the FDA's Cellular, Tissue and Gene Therapies Advisory Committee voted 9-3 against the effectiveness of Deramiocel for cardiomyopathy in Duchenne muscular dystrophy (DMD). This non-binding vote focused on a narrower indication than proposed, with the company noting supportive discussion on …

FDA Panel Says "No" To Capricor's DMD Drug Deramiocel, Citing "Fragile" Data; Shares Plunge

(RTTNews) - Shares of Capricor Therapeutics, Inc. (CAPR) have been hit hard this week following adverse regulatory developments related to Deramiocel, the company's investigational cell therapy for Duchenne muscular dystrophy-associated cardiomyopathy. Duchenne muscular dystrophy (DMD) is a devastating genetic disorder characterized by progressive weakness …

Capricor Duchenne cell therapy voted down by FDA panel

An FDA advisory panel voted against Capricor Therapeutics' experimental cell therapy, deramiocel, for Duchenne muscular dystrophy-related cardiomyopathy, citing insufficient evidence of effectiveness. This decision follows a contentious regulatory process and skepticism from FDA scientists regarding Capricor's data analysis. The FDA is expected to make …

Aprea Therapeutics plans Q4 2026 data update for APR-1051 trial

Aprea Therapeutics announced it expects to present clinical data from its Phase 1 ACESOT-1051 trial in Q4 2026. The trial, evaluating APR-1051 for advanced solid tumors, is expanding enrollment and will include combination regimens with standard-of-care therapies. The company anticipates completing dose escalation and …

Aprea Therapeutics Inc (APRE) Valuation: PE, PB & Fair Value Analysis

Aprea Therapeutics Inc (APRE) currently has a valuation score of 8.59, ranking 110th out of 384 companies in the Biotechnology & Medical Research industry. The company's P/E ratio is -0.42, which is significantly below its recent high and above its recent low. However, relevant …

Q&A: Aprea Therapeutics' Oren Gilad on WEE1 Inhibitor Data and the Company's DNA Damage Response Strategy

Oren Gilad, CEO of Aprea Therapeutics, discussed the company's WEE1 inhibitor, APR-1051, at BIO 2026, highlighting initial positive phase 1 data presented at ASCO 2026, including a confirmed partial response. APR-1051 is designed to minimize off-target effects compared to earlier WEE1 inhibitors, and Aprea …

UBS Remains a Buy on Capricorn Metals Ltd (CMM)

Capri Global Capital AUM Grows 62% In Q1 FY27

Aprea Therapeutics Inc (APRE) Risk Assessment: Volatility, Financial Risk & Investment Risk

Aprea Therapeutics Inc (APRE) has a current risk assessment score of 2.31, ranking it 220 out of 384 in the Biotechnology & Medical Research industry. The company's beta value of 1.46 indicates higher volatility compared to the S&P 500. The article details various risk …

CAPRICOR INVESTIGATION ALERT: Bragar Eagel & Squire, P.C. is Investigating Capricor Therapeutics, Inc. on Behalf of Capricor Stockholders and Encourages Investors to Contact the Firm

Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Capricor (CAPR) To Contact Him Directly To Discuss Their Options If you purchased or acquired stock in Capricor and would like to discuss your legal rights, contact Bragar Eagel …

Capri Holdings Is Maintained at Hold by TD Cowen

TD Cowen has maintained its "Hold" rating on Capri Holdings. This indicates the firm's neutral stance on the company's stock, suggesting investors should continue to hold their existing positions without buying more or selling.

FDA panel votes against Capricor's Duchenne heart disease therapy

A U.S. FDA advisory panel voted against the effectiveness data for Capricor Therapeutics' experimental cell therapy, deramiocel, intended for a heart condition associated with Duchenne muscular dystrophy. The nine-to-three vote mirrored FDA staff concerns regarding insufficient evidence of efficacy and questioned changes in key …

The Lancet Publishes HOPE-3 Data for Capricor Therapeutics’ Deramiocel in Duchenne Muscular Dystrophy

Capricor Therapeutics announced that The Lancet has published results from its pivotal Phase 3 HOPE-3 clinical trial for Deramiocel, an investigational cell therapy for Duchenne muscular dystrophy (DMD). The study demonstrated a significant 54% slowing of upper limb function decline and clinically meaningful cardiac …

Analysts Estimate Capri Holdings (CPRI) to Report a Decline in Earnings: What to Look Out for

Capri Holdings (CPRI) is expected to deliver a year-over-year decline in earnings on lower revenues when it reports results for the quarter ended June 2026. This widely-known consensus outlook gives a good sense of the company's earnings picture, but how the actual results compare …

Capricor and Replimune prep for FDA adcomms, Q2 earnings roll on, Sarepta’s new leader, more

The FDA is holding advisory committee meetings for therapies from Capricor Therapeutics and Replimune, with briefing documents indicating potential challenges for approval. Meanwhile, Q2 earnings reports continue with GSK announcing a $2.5 billion cost-cutting plan and AstraZeneca affirming its 2030 revenue target of $80 …

Aprea Therapeutics Inc (APRE) Technical Analysis: Support, Resistance, Indicators & Moving Averages

This article provides a technical analysis of Aprea Therapeutics Inc (APRE), focusing on its stock price momentum, support and resistance levels, and various technical indicators and moving averages. The stock currently has a price momentum score of 4.51 and is trading between a resistance …

Capri Global Capital Profit Doubles to Rs 353 Cr in Q1

Capri Global Capital hosts Q1FY27 investor call on Aug 3

Capri Global Capital Q1 Results: Earnings call recording available online

Capri Global Capital Teams Up With OpenAI to Implement Advanced AI in Lending Operations

Earnings call transcript: Capri Global Capital posts strong Q1 2026 growth

Capri (CPRI) Expected to Post Quarterly Earnings on Wednesday

Capral (ASX:CAA): Can Earnings and Net Cash Narrow Its Discount to Asset Backing?

J Kumar Infraprojects Q1 Results: Earnings Call Scheduled for Aug 7

Capricor Therapeutics (CAPR) Falls On FDA Doubts, Where Does Fair Value Sit?

Aprea Therapeutics Inc (APRE) Financial Health: Profitability & Balance Sheet Analysis

Aprea Therapeutics Inc (APRE) currently holds a financial score of 6.51, ranking 248th out of 385 in the Biotechnology & Medical Research industry, indicating robust financial status but low operating efficiency. The company's latest quarterly revenue decreased by 100.00% year-over-year, and net profit declined …

Aprea Therapeutics Inc (APRE) - Stock Score & Comprehensive Stock Analysis

This article provides a comprehensive stock analysis of Aprea Therapeutics Inc (APRE) by TradingKey, assigning it a score of 6.15/10. The analysis highlights the company's healthy fundamentals and significant growth potential, despite a recent weak stock market performance. It notes a high institutional ownership …

CAPR INVESTOR ALERT: Kirby McInerney LLP Announces Investigation Into Potential Securities Fraud

NEW YORK, July 28, 2026 (GLOBE NEWSWIRE) -- The law firm of Kirby McInerney LLP is investigating potential claims against Capricor Therapeutics, Inc. (“Capricor” or the “Company”) (NASDAQ: CAPR). The investigation concerns whether the Company and/or members of its senior management may have violated …

DJ Mediaprint & Logistics Ltd Revenue Breakdown – NSE:DJML